Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis (Q35186537)

7 August 2017

Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis (English)

1 reference

7 August 2017

Harold J Manley

1

1 reference

7 August 2017

Nicole M Allcock

series ordinal

2

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

7 August 2017

1 reference

7 August 2017

23

1 reference

7 August 2017

7

1 reference

7 August 2017

861-865

1 reference

Factors associated with medication-related problems in ambulatory hemodialysis patients.

7 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.7.861.32727

Glycemic control is a predictor of survival for diabetic patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.7.861.32727

Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.7.861.32727

Cellular mechanisms of insulin resistance in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.7.861.32727

Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.7.861.32727

Thiazolidinediones: a new class of antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.7.861.32727

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.7.861.32727

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.7.861.32727

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.7.861.32727

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.7.861.32727

Drug record discrepancies in an outpatient electronic medical record: frequency, type, and potential impact on patient care at a hemodialysis center

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.7.861.32727

Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.7.861.32727

Troglitazone has no effect on red cell mass or other erythropoietic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.7.861.32727

IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.7.861.32727

10.1592/PHCO.23.7.861.32727

21 January 2018

Identifiers

DOI

1 reference

release_3pvqv6yq35gennfpgclilbz7jm

7 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3pvqv6yq35gennfpgclilbz7jm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference